Woippy, May 18, 2026 at 08:00 CET – ABL Diagnostics (FR001400AHX6 – “ABLD”), a specialist in molecular diagnostics, bioinformatics and infectious disease solutions, today announces its strategic commitment to integrating Artificial Intelligence (AI) and Machine Learning (ML) architectures across its research and bioinformatics ecosystem.
By combining advanced computational innovation with a security-centric global data infrastructure, the company is positioning its technology to meet the most rigorous international standards for data integrity and pathogen analysis.
As molecular biology and microbiology continue to evolve toward increasingly data-driven approaches, ABL Diagnostics is evolving its data-driven strategy. By developing AI-ready frameworks within its internal R&D and operational processes, the company aims to accelerate the next generation of assay design and genomic interpretation. The objective is to further enhance innovation capabilities, improve productivity, strengthen competitiveness and optimize the overall efficiency of assay design, data analysis and development workflows.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer